← Back to Screener
Boundless Bio, Inc. Common Stock (BOLD)
Price$1.63
Favorite Metrics
Price vs S&P 500 (26W)21.40%
Price vs S&P 500 (4W)33.49%
Market Capitalization$36.52M
All Metrics
Book Value / Share (Quarterly)$4.40
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.11
Price vs S&P 500 (YTD)33.19%
EPS (TTM)$-2.60
10-Day Avg Trading Volume0.78M
EPS Excl Extra (TTM)$-2.60
EPS (Annual)$-2.60
ROI (Annual)-58.99%
Cash / Share (Quarterly)$4.80
ROA (Last FY)-37.05%
EBITD / Share (TTM)$-2.79
ROE (5Y Avg)-47.13%
Cash Flow / Share (Annual)$-2.11
P/B Ratio0.37x
P/B Ratio (Quarterly)0.27x
Net Income / Employee (Annual)$-2
ROA (TTM)-33.42%
EPS Incl Extra (Annual)$-2.60
Current Ratio (Annual)8.74x
Quick Ratio (Quarterly)8.58x
3-Month Avg Trading Volume0.20M
52-Week Price Return31.45%
Revenue / Employee (TTM)$0
52-Week High$1.78
EPS Excl Extra (Annual)$-2.60
26-Week Price Return25.38%
Quick Ratio (Annual)8.58x
13-Week Price Return31.45%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.74x
Enterprise Value$18.656
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.80
3-Month Return Std Dev72.08%
Net Income / Employee (TTM)$-2
ROE (Last FY)-58.99%
EPS Basic Excl Extra (Annual)$-2.60
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.60
ROI (TTM)-49.73%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)1.62%
Year-to-Date Return35.83%
5-Day Price Return42.98%
EPS Normalized (Annual)$-2.60
ROA (5Y Avg)-37.74%
Month-to-Date Return48.18%
EBITD / Share (Annual)$-2.79
ROI (5Y Avg)-47.13%
EPS Basic Excl Extra (TTM)$-2.60
P/B Ratio (Annual)0.27x
Book Value / Share (Annual)$4.40
Price vs S&P 500 (13W)30.76%
Beta1.08x
Revenue / Share (TTM)$0.00
ROE (TTM)-49.73%
52-Week Low$0.96
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.29
2.29
2.29
2.29
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BOLDBoundless Bio, Inc. Common Stock | — | — | — | — | $1.63 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Boundless Bio is a clinical-stage oncology company developing therapeutics that target extrachromosomal DNA (ecDNA), a driver of oncogene amplification in cancer. The company's lead program, BBI-355, is an oral CHK1 inhibitor designed to disrupt ecDNA replication and transcription, addressing an unmet need in patients with oncogene-amplified tumors.